Wall Street analysts expect IQVIA Holdings (IQV) to post quarterly earnings of $2.63 per share in its upcoming report, which indicates a year-over-year increase of 3.5%. Revenues are expected to be $3.77 billion, up 0.9% from the year-ago quarter.

Over the last 30 days, there has been a downward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.

Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.

While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.

Bearing this in mind, let's now explore the average estimates of specific IQVIA metrics that are commonly monitored and projected by Wall Street analysts.

Based on the collective assessment of analysts, 'Revenues- Technology & Analytics Solutions' should arrive at $1.52 billion. The estimate indicates a change of +4.4% from the prior-year quarter.

The consensus among analysts is that 'Revenues- Research & Development Solution' will reach $2.08 billion. The estimate suggests a change of -0.9% year over year.

The consensus estimate for 'Revenues- Contract Sales & Medical Solutions' stands at $183.42 million. The estimate indicates a year-over-year change of -3%.

The collective assessment of analysts points to an estimated 'Backlog' of $31.43 billion. Compared to the current estimate, the company reported $30.1 billion in the same quarter of the previous year.

Analysts expect 'Segment Profit- Technology & Analytics Solution' to come in at $365.56 million. Compared to the current estimate, the company reported $335 million in the same quarter of the previous year.

It is projected by analysts that the 'Segment Profit- Contract Sales & Medical Solutions' will reach $15.65 million. Compared to the present estimate, the company reported $13 million in the same quarter last year.

The average prediction of analysts places 'Segment Profit- Research & Development Solutions' at $471.69 million. Compared to the present estimate, the company reported $479 million in the same quarter last year.

View all Key Company Metrics for IQVIA here>>>

IQVIA shares have witnessed a change of -11.1% in the past month, in contrast to the Zacks S&P 500 composite's -0.7% move. With a Zacks Rank #4 (Sell), IQV is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

IQVIA Holdings Inc. (IQV) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research